Want to see HK:0460 full AI Analyst Report?
Top Page
Sihuan Pharmaceutical Holdings Group
(0460)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$0.80
▲(2.44% Upside)
Action:Reiterated
Date:07/15/26
The score is driven primarily by mixed financial performance: a meaningful 2025 earnings rebound and a manageable balance sheet are outweighed by weak and inconsistent cash-flow conversion. Technicals add pressure with a broadly downward trend (below key moving averages and negative MACD), while valuation remains a headwind given the high P/E and modest dividend yield.
Positive Factors
2025 Revenue Rebound
The 2025 revenue rebound indicates renewed demand for the company’s pharmaceutical portfolio and improved commercial execution in its PRC hospital and medical-channel markets. If sustained, stronger sales can support operating leverage, fund product development, and broaden the base for future earnings growth.
Negative Factors
Weak Cash-Flow Conversion
Negative operating and free cash flow alongside positive reported earnings signals weak conversion of accounting profits into usable funds. If this persists, the company may have less internally generated capital for research, launches, debt reduction, and shareholder returns, increasing financial flexibility risk.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue Rebound
The 2025 revenue rebound indicates renewed demand for the company’s pharmaceutical portfolio and improved commercial execution in its PRC hospital and medical-channel markets. If sustained, stronger sales can support operating leverage, fund product development, and broaden the base for future earnings growth.
Read all positive factors
Sihuan Pharmaceutical Holdings Group (0460) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.42B
Dividend Yield1.41%
Average Volume (3M)33.53M
Price to Earnings (P/E)19.8
Beta (1Y)1.10
Revenue Growth29.68%
EPS GrowthN/A
CountryHK
Employees2,843
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.03
Shares Outstanding9,329,999,000
10 Day Avg. Volume50,045,098
30 Day Avg. Volume33,527,574
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.72
Price to Sales (P/S)3.85
P/FCF Ratio-46.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$3.48B
Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model
Company Description
Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral v...
How the Company Makes Money
Sihuan Pharmaceutical makes money primarily by selling pharmaceutical products in the PRC. Its revenue model is driven by: (1) Product sales: The core revenue stream comes from sales of prescription drugs manufactured by the group and distributed ...
Sihuan Pharmaceutical Holdings Group Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.63B | 2.62B | 1.90B | 1.86B | 2.18B | 3.04B |
| Gross Profit | 1.73B | 1.80B | 1.24B | 1.30B | 1.49B | 2.43B |
| EBITDA | 636.80M | 642.61M | -208.66M | 334.31M | -1.54B | 931.69M |
| Net Income | 301.80M | 179.70M | -216.66M | -54.02M | -1.91B | 416.51M |
Balance Sheet | ||||||
| Total Assets | 11.63B | 11.64B | 10.53B | 11.54B | 12.14B | 14.50B |
| Cash, Cash Equivalents and Short-Term Investments | 3.72B | 4.10B | 3.63B | 4.48B | 4.79B | 5.79B |
| Total Debt | 969.22M | 1.01B | 942.76M | 1.26B | 1.29B | 1.08B |
| Total Liabilities | 4.67B | 4.73B | 5.58B | 6.40B | 6.50B | 5.35B |
| Stockholders Equity | 6.15B | 5.85B | 4.37B | 4.43B | 4.74B | 8.28B |
Cash Flow | ||||||
| Free Cash Flow | 42.67M | -218.06M | 57.51M | -95.93M | -355.97M | 64.28M |
| Operating Cash Flow | 73.91M | -23.56M | 243.89M | 199.49M | 46.49M | 665.29M |
| Investing Cash Flow | 518.25M | -296.48M | 758.24M | 169.88M | -1.66B | -337.57M |
| Financing Cash Flow | -279.00M | 358.16M | -1.26B | -419.56M | -238.93M | 750.66M |
Sihuan Pharmaceutical Holdings Group Technical Analysis
Negative
0.78
Price Trends
0.86
Negative
0.96
Negative
1.18
Negative
Market Momentum
-0.03
Positive
42.50
Neutral
45.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Negative. The current price of 0.78 is below the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.86, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.50 is Neutral, neither overbought nor oversold. The STOCH value of 45.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0460.
Sihuan Pharmaceutical Holdings Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$25.01B | 14.47 | 11.97% | 7.74% | -5.90% | -18.84% | |
68 Neutral | HK$28.21B | 5.95 | 7.92% | 5.36% | 7.94% | 52.83% | |
61 Neutral | HK$26.93B | 15.42 | 8.60% | 3.08% | 14.80% | -2.88% | |
59 Neutral | HK$36.34B | 12.78 | 6.64% | 6.34% | 6.58% | -4.29% | |
59 Neutral | HK$65.80B | 17.53 | 6.97% | 2.60% | 9.88% | 9.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$7.42B | 19.85 | 5.03% | 1.41% | 29.68% | ― |
* Healthcare Sector Average
HK:0460
Sihuan Pharmaceutical Holdings Group
0.78
-0.87
-52.94%
HK:0867
China Medical System Holdings
11.18
-2.77
-19.86%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
13.61
-3.90
-22.28%
HK:1513
Livzon Pharmaceutical Group
21.24
-13.29
-38.49%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.29
-9.07
-34.41%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.47
-0.26
-5.52%
Sihuan Pharmaceutical Holdings Group Corporate Events
Sihuan’s Xuanzhu Biopharm Strikes Exclusive Bireociclib Deal in Thailand
Sep 3, 2026
Sihuan Pharmaceutical’s non-wholly owned subsidiary Xuanzhu Biopharm has signed a tri-party commercial agreement with Thailand’s Innobic (Asia) and ZaoAn International for the exclusive commercialization of Bireociclib tablets in Thail...
Sihuan Pharmaceutical Grants 116 Million Performance-Based Share Awards
Sep 1, 2026
Sihuan Pharmaceutical Holdings Group has granted 116,150,000 share awards under its 2026 Share Incentive Scheme, equivalent to about 1.27% of its issued share capital, to a mix of executive management, related persons and 104 other employees. The ...
Sihuan Pharma Launches Share Buyback as Profit Surges on Aesthetics Push
Aug 27, 2026
Sihuan Pharmaceutical Holdings Group has stepped up its capital management by repurchasing 10 million shares on the open market at an average price of HK$0.8111 per share, representing about 0.11% of its issued share capital, with the stock to be ...
Sihuan Pharmaceutical Reshapes Leadership With CFO Exit and New Non-Executive Director
Aug 26, 2026
Sihuan Pharmaceutical announced that Ms. Miao Guili has resigned as executive director, deputy chief executive officer and chief financial officer, as well as co-chair of the board’s risk management committee, effective 26 August 2026, citin...
Sihuan Pharmaceutical Clarifies Board and Committee Structure
Aug 26, 2026
Sihuan Pharmaceutical Holdings Group Ltd. has announced the current composition of its board of directors, detailing the roles of its executive, non-executive and independent non-executive members. The disclosure also specifies membership and chai...
Sihuan Pharmaceutical Leans on Aesthetics and Innovation as Generic Drug Margins Erode
Aug 26, 2026
Sihuan Pharmaceutical reported interim revenue of RMB1,161.2 million for the six months ended 30 June 2026, up 1.3% year on year, as robust growth in medical aesthetics and innovative medicines offset sharp declines in generic drug sales. Medical ...
Sihuan Pharmaceutical Sets Board Meeting to Approve Interim Results and Dividend Plan
Aug 14, 2026
Sihuan Pharmaceutical Holdings Group Ltd., incorporated in Bermuda and listed in Hong Kong, operates in the pharmaceutical sector and markets its products mainly through its subsidiaries in regional healthcare markets. Its governance framework com...
Sihuan Pharmaceutical Updates Bermuda Registered Office Address
Jul 27, 2026
Sihuan Pharmaceutical Holdings Group Ltd. has announced that, effective 3 August 2026, its registered office and principal share registrar address in Bermuda will move to Richmond House, 12 Par-la-Ville Road, Hamilton HM 08. The company’s Ho...
Sihuan Pharmaceutical Flags 217% Profit Surge on Medical Aesthetics and Portfolio Gains
Jul 27, 2026
Sihuan Pharmaceutical has issued a positive profit alert for the six months ended 30 June 2026, indicating revenue of at least RMB1,140 million, roughly flat year-on-year, but a net profit of no less than RMB210 million, representing a surge of at...
Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of Anaprazole
Jun 30, 2026
Sihuan Pharmaceutical Holdings Group announced that China’s National Medical Products Administration has accepted a New Drug Application for a new indication of Anaprazole Sodium Enteric-coated Tablets, marketed as An Jiu Wei, for treating a...
Sihuan Pharmaceutical Shareholders Approve All AGM Resolutions and Capital Mandates
Jun 26, 2026
Sihuan Pharmaceutical Holdings Group reported that all resolutions put to shareholders at its 26 June 2026 annual general meeting were approved by poll, with 8.996 billion shares eligible to vote after excluding treasury shares and those held unde...
Sihuan’s Xuanzhu Biopharm Launches Phase III Trial for Anaprazole in H. pylori Therapy
Jun 22, 2026
Sihuan Pharmaceutical’s subsidiary Xuanzhu Biopharm has begun a Phase III clinical trial of its innovative proton pump inhibitor Anaprazole Sodium Enteric-coated Tablets as part of a bismuth-containing quadruple therapy for Helicobacter pylo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.